Linked Life Data

11839655

Source:http://linkedlifedata.com/resource/pubmed/id/11839655

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2002-2-12
pubmed:abstractText
Selecting an experimental arm for a Phase III trial is based on the results of Phase II investigations. Historical results show that this paradigm leads to the failure of many experimental therapies in the Phase III setting. This is the result of failures in the Phase II design that include differences in the patient populations and basing sample size determinations on levels of benefit derived from surrogate end points that do not accurately reflect the end point of interest in the Phase III study. An additional factor is how to ensure that the experimental therapy chosen was the best available at the time.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
1078-0432
pubmed:author
pubmed:issnType
Print
pubmed:volume
8
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
400-4
pubmed:dateRevised
2007-11-14
pubmed:meshHeading
pubmed:year
2002
pubmed:articleTitle
Picking the winners in a sea of plenty.
pubmed:affiliation
Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA.
pubmed:publicationType
Journal Article, Clinical Trial, Research Support, U.S. Gov't, P.H.S., Research Support, Non-U.S. Gov't, Clinical Trial, Phase II, Clinical Trial, Phase III